Free Trial

Organigram (TSE:OGI) Hits New 1-Year High - Here's Why

Organigram logo with Medical background

Key Points

  • Organigram Holdings Inc. shares hit a new 52-week high, trading as high as C$2.89 with a recent price of C$2.85, marking a 5.6% increase.
  • The company has a market capitalization of C$380.23 million, a PE ratio of 236.67, and significant debt-to-equity ratio of 3.07.
  • Organigram is a Canadian licensed producer of cannabis products, focusing on indoor-grown cannabis for both patients and recreational consumers.
  • Five stocks to consider instead of Organigram.

Organigram Holdings Inc. (TSE:OGI - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as C$2.89 and last traded at C$2.85, with a volume of 396023 shares. The stock had previously closed at C$2.69.

Organigram Stock Up 5.6%

The company's fifty day moving average is C$2.32 and its 200-day moving average is C$1.94. The company has a market capitalization of C$380.23 million, a PE ratio of 236.67, a price-to-earnings-growth ratio of 0.42 and a beta of 2.19. The company has a debt-to-equity ratio of 3.07, a quick ratio of 2.62 and a current ratio of 3.36.

Organigram Company Profile

(Get Free Report)

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Organigram Right Now?

Before you consider Organigram, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.

While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.